Navigation Links
Beating blindness with vegetable oil
Date:8/15/2013

Scientists working at the Research Center on Aging at the Health and Social Services Centre University Institute of Geriatrics of Sherbrooke (CSSS-IUGS) have been studying strategies for protecting retinal pigment epithelium (RPE) cells. Dysfunction of the RPE is found in retinopathy and age-related macular degeneration, which is the leading cause of blindness of elderly people in developed countries.

Findings published today in the Canadian Journal of Physiology and Pharmacology suggest that incubating retinal cells with vegetable oils induces biochemical and biophysical changes in the cell membrane, which may have a beneficial effect in preventing or slowing the development of retinopathy.

"Membrane fluidity, which refers to the viscosity of the lipid bi-layer of a cell membrane, is a marker of the cell function," explained Prof. A. Khalil, professor at the Universit de Sherbrooke and principal investigator of the study. "A decrease of membrane fluidity can affect the rotation and diffusion of proteins and other bio-molecules within the membrane, thereby affecting the functions of these molecules. Whereas, an increase in membrane fluidity makes for a more flexible membrane and facilitates the transmission of light through the eye."

The researchers discovered that vegetable oil fatty acids incorporate in retina cells and increase the plasma membrane fluidity. They concluded that a diet low in trans-unsaturated fats and rich in omega-3 fatty acids and olive oil may reduce the risk of retinopathy. In addition, the research suggests that replacing the neutral oil used in eye drops with oil that possesses valuable biological properties for the eye could also contribute to the prevention of retina diseases.


'/>"/>

Contact: Jenny Ryan
jenny.ryan@nrcresearchpress.com
Canadian Science Publishing (NRC Research Press)
Source:Eurekalert

Page: 1

Related biology news :

1. Beating famine: Sustainable food security through land regeneration in a changing climate
2. Embryonic blood vessels that make blood stem cells can also make beating heart muscles
3. Antioxidant shown to reduce blindness risk in extremely premature babies
4. Massachusetts Eye and Ear researchers discover elusive gene that causes a form of blindness from birth
5. New cause of child blindness identified
6. Singapore scientists find genes associated with glaucoma, a major cause of eye blindness
7. First in the world - Singapore scientists discover genes responsible for cornea blindness
8. Long-suspected cause of blindness from eye disease disproved
9. John Moores gives $2 million to Scripps Research to develop river blindness field test
10. Should we play hide-and-go-seek with our childrens vegetables?
11. Eat your vegetables! New book redefines how to raise healthy eaters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... technical, managerial and financial components of healthcare delivery to ... Disease) patient will be the topic of Stevens Institute ... October 31, 2007, from 3-5 p.m. in Room 122 ... Streets in Hoboken, NJ). , Roundtable participants will discuss ...
... a 46 percent increase in lifespan, raising the tantalizing ... are also taking an anti-aging medication. Results of the ... Lithgow, PhD, are currently published online in the Journal ... to treat mood affective disorders, including bipolar disease for ...
... daily commute may be taking more of a toll than ... of Southern California (USC) and the California Air Resources Board ... exposure to harmful air pollutants occurs while people are traveling ... spends about six percent (1.5 hours) of his or her ...
Cached Biology News:Stevens Health, Technology, and Society roundtable: Oct. 31 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Time spent in car drives up air pollution exposure 2
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... December 19, 2014 The empty ... the rising ageing population and technological innovations in ... nutraceutical industries are catalysing the growth of the ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , ... well as new entrants/smaller firms to gauge the ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 ... Lilly and Company (NYSE: LLY ) and ... positive results from a phase 2 study evaluating the ... on glycemic control in patients with type 2 diabetes. ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... a randomized pivotal trial of pixantrone for the treatment ... the  U.S. Food and Drug Administration,s (the "FDA") Division ... trial, referred to as the PIX-R or PIX 306 ...
... release is available in German . , From the ... to the strings and sound box of a guitar or violin, ... actual mechanical vibrations of these instruments create acoustic waves that we ... related to the decay of the vibration amplitude, that is, the ...
Cached Biology Technology:Exenatide Once Monthly Showed Positive Results in Phase 2 Study 2Exenatide Once Monthly Showed Positive Results in Phase 2 Study 3Exenatide Once Monthly Showed Positive Results in Phase 2 Study 4Exenatide Once Monthly Showed Positive Results in Phase 2 Study 5Exenatide Once Monthly Showed Positive Results in Phase 2 Study 6Exenatide Once Monthly Showed Positive Results in Phase 2 Study 7FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5How long does a tuning fork ring? 2
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
GOAT ANTI SLI...
Protein Phosphorylation...
ANTI L-DOPA...
Biology Products: